metaPreg - Adalimumab during pregnancy

Adalimumab

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.51 [1.06, 5.97]	31%	5 studies	62	380	not evaluable	ROB
Major congenital malformations	2.30 [0.94, 5.64]	37%	4 studies	62	378	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Preterm (< 37 weeks)	1.17 [0.40, 3.41]	0%	3 studies	42	220	not evaluable	ROB
Small for gestational age (weight)	0.80 [0.40, 1.61]	0%	2 studies	30	208	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Caesarean	-	-	0 study
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Neonatal infections	0.96 [0.41, 2.23]	0%	2 studies	66	337	not evaluable	ROB
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Early intrauterine death (< 22 weeks)	2.39 [0.78, 7.30]	0%	2 studies	32	260	not evaluable	ROB
Elective/induced termination of pregnancy	1.95 [0.15, 24.78]	0%	2 studies	1	260	not evaluable	ROB
Therapeutic terminations of pregnancy	-	-	0 study
2 non statistically significant endpoints reported in only one study